French Pharma Stock News

TotalEnergies (ENXTPA:TTE) is back in focus after teaming up with Tikehau Capital to co fund an electric vehicle charging platform for urban public spaces in Belgium and the Netherlands. See our latest analysis for TotalEnergies. Those EV charging plans come as TotalEnergies’ share price, at €62.56, has logged an 11.5% year to date share price return and a 17.5% 90 day share price return, while the 5 year total shareholder return of 143.0% points to strong longer term momentum. If this kind...

In recent days, Schneider Electric and its ETAP subsidiary introduced a physics-based digital twin and expanded One Digital Grid platform at the DTECH trade show, aiming to help utilities and critical infrastructure better model, monitor, and respond to grid disruptions. By linking real-time operations with engineering-grade simulation and GIS intelligence, Schneider Electric is pushing utilities beyond static grid maps toward predictive, scenario-based resilience planning. We’ll now...

The relaunch of the 2026 Renault Duster in India, featuring a full redesign, hybrid powertrain options and extensive accessories, has drawn renewed attention to Renault (ENXTPA:RNO) and how this product push might relate to its stock. See our latest analysis for Renault. That Duster relaunch lands after a weak patch for Renault’s shares, with a 30 day share price return of 9.78% decline and a 1 year total shareholder return of 29.50% loss, indicating that sentiment has been under pressure...

Arkema and battery separator producer Senior recently signed a Memorandum of Understanding to deepen cooperation across the battery value chain, from advanced adhesion and coating technologies to emerging semi-solid cell manufacturing. This partnership highlights how Arkema’s specialty materials, such as Kynar PVDF and Incellion solutions, are being integrated into next-generation battery designs to improve safety, durability and manufacturing efficiency. We will now examine how this push...

Sanofi (ENXTPA:SAN) reported positive Phase 3 results for its investigational oral therapy venglustat in neurological symptoms of type 3 Gaucher disease. The company plans global regulatory filings for venglustat following these data. Rezurock received a positive conditional recommendation for approval in Europe for chronic graft versus host disease after a previous negative opinion was reversed. For you as an investor, these updates sit at the core of what Sanofi focuses on: treatments for...

The board of Omer-Decugis & Cie SA ( EPA:ALODC ) has announced that it will be paying its dividend of €0.18 on the 13th...

In late January 2026, Société Générale Société anonyme completed two €30,000,000 fixed-income offerings of callable senior unsecured notes and reported that its €1.00 billion share buy-back program was over 95% executed. This combination of bond issuance and substantial capital return highlights how the bank is actively managing its balance sheet while reducing its share count. We will now examine how the near-completion of the €1.00 billion share buy-back shapes Société Générale’s broader...

As the eurozone continues its modest recovery, with confidence strengthening and investment bolstering economic output, European markets are showing resilience amidst geopolitical uncertainties. In this environment, dividend stocks can offer investors a steady income stream and potential stability, making them an attractive consideration for those looking to navigate the current market dynamics.

Ubisoft Entertainment (ENXTPA:UBI) has called a special investor event to outline a major organizational, operational and portfolio reset, aimed at reclaiming creative leadership and restoring what management describes as sustainable growth. See our latest analysis for Ubisoft Entertainment. The reset comes after a tough stretch for investors, with the share price down around 36% over the past month and about 63% total shareholder return decline over one year, signaling that sentiment has...

Manitou BF (ENXTPA:MTU) drew fresh attention after its Q4 2025 sales and trading statement call on 28 January, followed by a 21.11% intraday stock surge on 30 January driven by heavy trading volume. See our latest analysis for Manitou BF. That sharp Q4 trading update and the €22.85 share price sit within a strong run, with a 7-day share price return of 28.37% and a 90-day share price return of 29.10%. The 1-year total shareholder return of 10.34% shows a more measured longer term outcome and...

Etablissements Maurel & Prom S.A. recently reported that fourth-quarter 2025 sales were US$88 million and full-year 2025 sales were US$578 million, compared with US$808 million for the prior year. The company also disclosed that annual production edged up to 37,096 boepd from 36,222 boepd, highlighting a disconnect between higher output and lower reported sales. We will now examine how the contrast between rising production and weaker full-year sales shapes Etablissements Maurel & Prom's...

Vinci (ENXTPA:DG) is back in focus after its construction arm won a €144 million contract from Jamaica’s National Water Commission to upgrade drinking water infrastructure under the Western Water Resilience Programme. See our latest analysis for Vinci. At a share price of €122.55, Vinci has a 7 day share price return of 3.20% and a 90 day share price return of 4.61%, while the 1 year total shareholder return of 20.77% suggests momentum has been positive rather than fading. If this kind of...

It's not a stretch to say that LACROIX Group SA's ( EPA:LACR ) price-to-sales (or "P/S") ratio of 0.1x right now seems...

Key Insights Insiders appear to have a vested interest in L.D.C's growth, as seen by their sizeable ownership 57% of...

With a price-to-earnings (or "P/E") ratio of 22.2x Signaux Girod S.A. ( EPA:ALGIR ) may be sending bearish signals at...

Key Insights The considerable ownership by public companies in Imerys indicates that they collectively have a greater...

In January 2026, Getlink SE reported unaudited consolidated revenue of €384 million for the fourth quarter of 2025, up from €325 million a year earlier, while full-year 2025 revenue came in at €1.60 billion compared with €1.61 billion in 2024. The combination of strong quarterly growth and essentially flat annual revenue offers investors a contrasting picture of Getlink’s recent operating momentum. We will now examine how this contrast between robust fourth-quarter revenue growth and flat...

ABIVAX Société Anonyme (ENXTPA:ABVX) is drawing attention after reporting that its lead drug candidate obefazimod showed efficacy with a clean safety profile in a Phase 3 ulcerative colitis trial, alongside plans for further pivotal studies. See our latest analysis for ABIVAX Société Anonyme. The recent Phase 3 ulcerative colitis result and takeover speculation arrive after a mixed stretch for the share price, with a 1 day share price return of 2.99%, a 30 day share price return decline of...

Vetoquinol (ENXTPA:VETO) has released unaudited sales for the fourth quarter and full year 2025, with quarterly revenue at €141.5 million and full year sales at €525.7 million, compared with €539.2 million in 2024. See our latest analysis for Vetoquinol. The latest sales update lands after a period where momentum in Vetoquinol’s share price has been picking up. The 90 day share price return is 19.72% and the 1 year total shareholder return is 24.24%, even though the 5 year total shareholder...

What COFACE’s recent performance numbers tell you With no single headline event driving attention, COFACE (ENXTPA:COFA) is drawing interest as investors weigh its recent share performance and fundamentals, including a €15.75 last close and a value score of 4. See our latest analysis for COFACE. Recent share price momentum has been steady rather than sharp, with a 9.38% 90 day share price return and a 9.26% 1 year total shareholder return, alongside a much stronger 61.90% 3 year total...

With no single headline event driving attention, Pluxee (ENXTPA:PLX) is drawing interest after a period of weaker share performance, including a 16% decline over the past month and a 51% negative total return over the past year. See our latest analysis for Pluxee. That 15.63% 30 day share price decline and 33.39% 90 day share price return, alongside a 50.73% 1 year total shareholder return decline, points to fading momentum as investors reassess Pluxee’s risk and growth profile around its...

On 1 February 2026, Eramet’s Board of Directors dismissed Chief Executive Officer Paulo Castellari over disagreements on operating methods and appointed Chairwoman Christel Bories as interim CEO while it searches for a permanent replacement. The Board’s move, taken amid a challenging operating backdrop, highlights ongoing tension between leadership approach and the company’s focus on safety, operational performance and cost reduction. We’ll now examine how this abrupt leadership change,...

The new long term alliance between Dassault Systèmes (ENXTPA:DSY) and NVIDIA to build industrial AI infrastructure places the 3DEXPERIENCE and OUTSCALE platforms at the center of virtual twin, AI factory and World Model development. See our latest analysis for Dassault Systèmes. Even with the NVIDIA alliance and recent AI focused events such as 3DEXPERIENCE World in Houston and the Singapore Airshow presence, Dassault Systèmes’ 1 year total shareholder return of 44.62% and 90 day share price...

Why this latest trading update matters for GL Events (ENXTPA:GLO) GL Events (ENXTPA:GLO) has just released its fourth quarter and full year 2025 revenue figures alongside a confirmation of improved operating margin guidance, providing fresh information on both business momentum and profitability expectations. See our latest analysis for GL Events. The latest trading statement seems to have caught investors' attention, with a 30 day share price return of 12.31% and a 90 day share price return...